Volume 7, Issue 3 (7-2017)                   Iran J Ped Hematol Oncol 2017, 7(3): 180-192 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Pourrajab F, Yazdani Elahabad P I, Hekmatimoghaddam S. The Efficacy of Toll-Like Receptors in Awakening Dendritic Cell/Natural Killer Cell System for Eradication of Tumors. Iran J Ped Hematol Oncol 2017; 7 (3) :180-192
URL: http://ijpho.ssu.ac.ir/article-1-324-en.html
Hematology and Oncology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Abstract:   (2368 Views)

Natural killer (NK) cells are effector cells of the innate immune system that exert direct cytotoxic functions. Ubiquitously-expressed toll-like receptors (TLRs) have been recognized as one of the major components promoting dendritic cell (DC) maturation, which may induce polarized immune responses beneficial to cancer immunotherapy. TLR-activated NK cells and DCs are prerequisite for robust activation of the innate immune system against tumors. Recently, some medical research and clinical trials have proposed NK cells as a new therapy and potential strategy in both children and adults with those cancers which cannot be cured with the usual treatment modalities. As an example, the importance of DC/NK antitumor immunity in the outcome of breast and other cancers is recently recognized. Therefore, considering strategies which exploit TLR-mediated immunity in concordance with DC/NK system holds strong potential for cancer therapy. This review addresses the current knowledge about the potential role of TLR in tumor immunotherapy

Full-Text [PDF 382 kb]   (869 Downloads)    
Type of Study: Research | Subject: Heart
Received: 2016/01/24 | Accepted: 2016/10/28 | Published: 2017/07/16

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Journal of Pediatric Hematology and Oncology

Designed & Developed by : Yektaweb